The 23rd International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place in Boston, MA on September 18–20, 2026. Esteemed experts gathered to discuss the latest research findings in NHL and strategies to enhance patient outcomes. iwNHL 2026 was supported by Platinum Sponsors: AbbVie, AstraZeneca, Genentech, and Genmab; Gold Sponsors: BeOne Medicines and Bristol Myers Squibb; Silver Sponsors: Caribou Biosciences, Eli Lilly and Company, and Novartis; Bronze Sponsors: ADC Therapeutics, Lyell Immunopharma, Natera, Nurix Therapeutics, Regeneron Pharmaceuticals, and Secura Bio; and Supporter: Arvinas. Sponsors of the workshop have no influence over the production of content.
R01
Controversies in T-Cell Lymphoma
›
R02
Controversies in Mantle Cell Lymphoma
›
R03
Defining Risk with ctDNA
›
R04
Translational Research in Aggressive Lymphomas
›
R05
Novel Therapies and Targeted Degraders
›
R06
Expanding CAR T-Cell Therapy
›
R07
Bispecific and Trispecific Antibodies in NHL
›
R08
CAR T-Cells Stuck in Second Gear
›
R09
Why Come to iwNHL?
›
R01
Controversies in T-Cell Lymphoma
Participants